Latest news from Actinium Pharmaceuticals, Inc. on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/novel-approaches-using-targeted-immunotherapeutics-help-older-patients-undergoing-bone-marrow-transplantations/?sc=rsin /articles/novel-approaches-using-targeted-immunotherapeutics-help-older-patients-undergoing-bone-marrow-transplantations/?sc=rsin Mon, 08 Jun 2015 08:30:00 EST Bone marrow transplant and hematology specialist Hillard M. Lazarus, MD, Professor of Medicine at Case Western Reserve University (CWRU) School of Medicine Actinium Pharmaceuticals, Inc. /articles/experts-in-leukemia-and-bone-marrow-transplant-prepare-for-upcoming-pivotal-trial-of-innovative-targeted-payload-immunotherapy/?sc=rsin /articles/experts-in-leukemia-and-bone-marrow-transplant-prepare-for-upcoming-pivotal-trial-of-innovative-targeted-payload-immunotherapy/?sc=rsin Tue, 09 Dec 2014 08:00:00 EST If approved, Iomab-B should increase the number of patients eligible for curative bone marrow transplant (BMT, also known as HSCT) and improve clinical outcomes. Actinium Pharmaceuticals, Inc. /articles/experts-in-leukemia-treatment-support-ongoing-trials-for-novel-alpha-radiolabeled-antibody-treatment/?sc=rsin /articles/experts-in-leukemia-treatment-support-ongoing-trials-for-novel-alpha-radiolabeled-antibody-treatment/?sc=rsin Tue, 09 Dec 2014 05:00:00 EST Since intensive chemotherapy is associated with a high mortality rate and limited benefits to high risk patients, low intensity treatments such as Actimab-A could potentially extend overall survival in elderly patients while significantly decreasing traditional chemotherapy related toxicities, including treatment related early mortality. Actinium Pharmaceuticals, Inc. /articles/innovative-targeted-payload-therapy-demonstrated-extension-of-overall-survival-to-9-1-months-in-elderly-patients-with-secondary-acute-myeloid-leukemia/?sc=rsin /articles/innovative-targeted-payload-therapy-demonstrated-extension-of-overall-survival-to-9-1-months-in-elderly-patients-with-secondary-acute-myeloid-leukemia/?sc=rsin Thu, 06 Nov 2014 09:00:00 EST Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML). Actinium Pharmaceuticals, Inc. /articles/making-bone-marrow-transplants-more-accessible-for-aml-patients-with-new-therapy/?sc=rsin /articles/making-bone-marrow-transplants-more-accessible-for-aml-patients-with-new-therapy/?sc=rsin Thu, 13 Feb 2014 08:00:00 EST An increasing number of prospective patients for bone marrow transplant are over age 55, but many in this group who need it are ruled ineligible because high-dose chemotherapy traditionally preceding it is in many cases lethal to such patients. Actinium Pharmaceuticals, Inc., a New York City-based biotech company, has developed a treatment in which a patient can be prepared for a transplant in a way that eliminates the need for multiple rounds of high-dose chemotherapy. Actinium Pharmaceuticals, Inc.